Synergistic Gene Expression Systems for Rod Photoreceptors

The present invention integrates the SYNP161 promoter with distinct technologies such as AI, IoT, blockchain, and new materials to create novel systems for targeted gene expression in rod photoreceptors, offering improved precision, efficiency, and personalized treatment options.

The original patent disclosed the SYNP161 promoter for gene expression in rod photoreceptors, but it had limitations in terms of regulation, precision, and scalability. The new inventive concept addresses these limitations by incorporating synergistic combinations of technologies to create more powerful and adaptable systems.

The inventive concept comprises a nucleic acid sequence of at least 150 base pairs and having at least 95% identity to the sequence of SEQ ID NO:1, operably linked to a gene encoding for a protein of interest. This sequence is integrated with an AI-powered gene regulation module for optimizing gene expression in response to environmental stimuli, a blockchain technology for secure data management, an IoT-enabled sensor for real-time monitoring, or a biocompatible material for ocular implants. The system enables targeted gene expression in rod photoreceptors, allowing for personalized gene therapy, gene editing, and machine learning-driven predictions of gene expression patterns.

The new claims introduce a synergistic combination of the SYNP161 promoter with distinct technologies, providing a novel and non-obvious solution for targeted gene expression in rod photoreceptors. The integration of AI, IoT, blockchain, and new materials with the promoter sequence enables a more efficient, precise, and adaptable system that was not anticipated by the original patent.

Alternative embodiments may include variations in the AI-powered gene regulation module, such as using different machine learning algorithms or incorporating additional data sources. The IoT-enabled sensor could be replaced with other monitoring systems, and the biocompatible material could be modified for use in different implantable devices. These variations would ensure broad conceptual coverage and adaptability to different applications.

The inventive concept has significant commercial potential in the fields of gene therapy, gene editing, and ocular implants. The integration of AI, IoT, blockchain, and new materials could lead to more efficient and personalized treatment options, addressing a significant market need in the field of ophthalmology.